ProQR Therapeutics
PRQR
38 hedge funds and large institutions have $241M invested in ProQR Therapeutics in 2015 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 8 closing their positions.
40% more capital invested
Capital invested by funds: $173M → $241M (+$68.4M)
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
30% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 10
9% more funds holding
Funds holding: 35 → 38 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$44.4M |
| 2 |
Millennium Management
New York
|
+$10.8M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$8.43M |
| 4 |
Jennison Associates
New York
|
+$8.12M |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$7.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
PointState Capital
New York
|
-$3.76M |
| 2 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$3.75M |
| 3 |
DM
Deerfield Management
New York
|
-$3.52M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.82M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.66M |
PRQR Hedge Fund Activity: Q1 2015 in Review
38 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q1 2015, worth a combined $241M — up 40% from $173M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new PRQR positions and 8 closed out — a net gain of 3 holders — while 13 added to existing stakes and 10 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $44.4M. The largest seller was PointState Capital, exiting entirely with an estimated $3.76M sold.
- 38 institutional investors held ProQR Therapeutics (PRQR) as of Q1 2015, up from 35 in Q4 2014.
- Funds reported $241M of ProQR Therapeutics stock for Q1 2015, up 40% quarter-over-quarter.
- 11 funds opened new ProQR Therapeutics positions in Q1 2015 and 8 closed out, a net change of +3 holders.
- The largest ProQR Therapeutics buyer in Q1 2015 was Fidelity Investments, an estimated $44.4M added.
- The largest ProQR Therapeutics seller in Q1 2015 was PointState Capital, an estimated $3.76M sold.
Based on aggregated 13F filings for Q1 2015.